Search Results - "WALKER, Alison R"

Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia by XIAOMENG HUANG, SCHWIND, Sebastian, BLUM, William, PERROTTI, Danilo, BYRD, John C, BLOOMFIELD, Clara D, CALIGIURI, Michael A, LEE, Robert J, GARZON, Ramiro, MUTHUSAMY, Natarajan, LEE, Ly James, MARCUCCI, Guido, BO YU, SANTHANAM, Ramasamy, HONGYAN WANG, HOELLERBAUER, Pia, MIMS, Alice, KLISOVIC, Rebecca, WALKER, Alison R, CHAN, Kenneth K

“…miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML), namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment…”
Get full text

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines by DeFilipp, Zachariah, Ciurea, Stefan O., Cutler, Corey, Robin, Marie, Warlick, Erica D., Nakamura, Ryotaro, Brunner, Andrew M., Dholaria, Bhagirathbhai, Walker, Alison R., Kröger, Nicolaus, Bejanyan, Nelli, Atallah, Ehab, Tamari, Roni, Solh, Melhem M., Percival, Mary-Elizabeth, de Lima, Marcos, Scott, Bart, Oran, Betul, Garcia-Manero, Guillermo, Hamadani, Mehdi, Carpenter, Paul, DeZern, Amy E.

“…The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed…”
Get full text

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 by Mims, Alice S, Mishra, Anjali, Orwick, Shelley, Blachly, James, Klisovic, Rebecca B, Garzon, Ramiro, Walker, Alison R, Devine, Steven M, Walsh, Katherine J, Vasu, Sumithira, Whitman, Susan, Marcucci, Guido, Jones, Daniel, Heerema, Nyla A, Lozanski, Gerard, Caligiuri, Michael A, Bloomfield, Clara D, Byrd, John C, Piekarz, Richard, Grever, Michael R, Blum, William

“…partial tandem duplication occurs in approximately 5-10% of patients with acute myeloid leukemia and is associated with adverse prognosis. wild type is…”
Get full text

How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia by Walker, Alison R

“…Until recently, treatment options for patients with acute myeloid leukemia (AML) were limited to cytotoxic chemotherapeutic agents that possessed little…”
Get full text

Dying a fiery death: pyroptosis in MDS by Walker, Alison R.

Get full text

Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial by El-Jawahri, Areej, LeBlanc, Thomas W, Kavanaugh, Alison, Webb, Jason A, Jackson, Vicki A, Campbell, Toby C, O'Connor, Nina, Luger, Selina M, Gafford, Ellin, Gustin, Jillian, Bhatnagar, Bhavana, Walker, Alison R, Fathi, Amir T, Brunner, Andrew M, Hobbs, Gabriela S, Nicholson, Showly, Davis, Debra, Addis, Hilena, Vaughn, Dagny, Horick, Nora, Greer, Joseph A, Temel, Jennifer S

“…Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during their…”
Get more information

Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression by Walker, Alison R, Byrd, John C, Blachly, James S, Bhatnagar, Bhavana, Mims, Alice S, Orwick, Shelley, Lin, Tara L, Crosswell, Howland E, Zhang, Danjie, Minden, Mark D, Munugalavadla, Veerendra, Long, Lauren, Liu, Jinfeng, Pan, Yang, Oellerich, Thomas, Serve, Hubert, Rao, Arati V, Blum, William G

“…Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to and…”
Get full text

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML by Jeon, Jae Yoon, Zhao, Qiuhong, Buelow, Daelynn R., Phelps, Mitch, Walker, Alison R., Mims, Alice S., Vasu, Sumithira, Behbehani, Gregory, Blachly, James, Blum, William, Klisovic, Rebecca B., Byrd, John C., Garzon, Ramiro, Baker, Sharyn D., Bhatnagar, Bhavana

“…Summary Activating FLT3 internal tandem duplication ( FLT3 -ITD) mutations in acute myeloid leukemia (AML) associate with inferior outcomes. We determined that…”
Get full text

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study by Bhatnagar, Bhavana, Zhao, Qiuhong, Mims, Alice S., Vasu, Sumithira, Behbehani, Gregory K., Larkin, Karilyn, Blachly, James S., Blum, William, Klisovic, Rebecca B., Ruppert, Amy S., Orwick, Shelley, Oakes, Christopher, Ranganathan, Parvathi, Byrd, John C., Walker, Alison R., Garzon, Ramiro

“…Current treatment options for older and relapsed or refractory (R/R) acute myeloid leukemia (AML) patients are limited and represent an unmet need. Based on…”
Get full text

Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia by Cremer, Anjali, Ellegast, Jana M, Alexe, Gabriela, Frank, Elizabeth S, Ross, Linda, Chu, S Haihua, Pikman, Yana, Robichaud, Amanda, Goodale, Amy, Häupl, Björn, Mohr, Sebastian, Rao, Arati V, Walker, Alison R, Blachly, James S, Piccioni, Federica, Armstrong, Scott A, Byrd, John C, Oellerich, Thomas, Stegmaier, Kimberly

“…Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown…”
Get more information

Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia by Bhatnagar, Bhavana, Zhao, Qiuhong, Mims, Alice S, Vasu, Sumithira, Behbehani, Gregory K, Larkin, Karilyn, Blachly, James S, Badawi, Mohamed A, Hill, Kasey L, Dzwigalski, Kyle R, Phelps, Mitch A, Blum, William, Klisovic, Rebecca B, Ruppert, Amy S, Ranganathan, Parvathi, Walker, Alison R, Garzon, Ramiro

“…Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clinical trials of relapsed/refractory (R/R)…”
Get full text

Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia by Walker, Alison R., Wang, Hongyan, Walsh, Katherine, Bhatnagar, Bhavana, Vasu, Sumithira, Garzon, Ramiro, Canning, Renee, Geyer, Susan, Wu, Yue-Zhong, Devine, Steven M., Klisovic, Rebecca, Blum, William, Marcucci, Guido

“…Targeting aberrant tyrosine kinase activity may impact clinical outcome in acute myeloid leukemia (AML). We conducted a phase I study of the tyrosine kinase…”
Get full text

Phase I study of AR-42 and decitabine in acute myeloid leukemia by Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Blum, William, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Geyer, Susan, Zhao, Qiuhong, Garzon, Ramiro, Marcucci, Guido, Phelps, Mitch A., Walker, Alison R.

“…This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling…”
Get full text

Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia by DeAngelo, Daniel J., Walker, Alison R., Schlenk, Richard F., Sierra, Jorge, Medeiros, Bruno C., Ocio, Enrique M., Röllig, Christoph, Strickland, Stephen A., Thol, Felicitas, Valera, Sue-zette, Dasgupta, Kohinoor, Berkowitz, Noah, Stuart, Robert K.

“…•Novel therapeutic agents are needed for treatment of high-risk AML.•Panobinostat plus standard chemotherapy is safe and effective in high-risk AML.•The RP2D…”
Get full text

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers by Walker, Alison R, Marcucci, Guido

“…The presence or absence of cytogenetic and molecular abnormalities present at the time of diagnosis of acute myeloid leukemia (AML) not only provides important…”
Get more information

The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent by Ozga, Michael, Huang, Ying, Blachly, James S., Grieselhuber, Nicole R., Wall, Sarah, Larkin, Karilyn, Haque, Tamanna, Walker, Alison R., Bhatnagar, Bhavana, Behbehani, Gregory, Vasu, Sumithira, Maakaron, Joseph E., Lustberg, Mark, Mims, Alice S.

“…Newly diagnosed patients with acute myeloid leukemia (AML) who receive induction with a hypomethylating agent (HMA) are often neutropenic with an increased…”
Get full text

Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy by Vaughn, John L, Kline, David, Denlinger, Nathan M, Andritsos, Leslie A, Exline, Matthew C, Walker, Alison R

Get full text

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance) by Walker, Alison R., Marcucci, Guido, Yin, Jun, Blum, William, Stock, Wendy, Kohlschmidt, Jessica, Mrózek, Krzysztof, Carroll, Andrew J., Eisfeld, Ann-Kathrin, Wang, Eunice S., Jacobson, Sawyer, Kolitz, Jonathan E., Thakuri, Mohan, Sutamtewagul, Grerk, Vij, Ravi, Stuart, Robert K., Byrd, John C., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.

“…Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with…”
Get full text

Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients by Koenig, Kristin L., Curley, Thomas P., Mani, Shylaja, Keiter, Ashleigh, Zhao, Qiuhong, Behbehani, Gregory K., Bhatnagar, Bhavana, Blachly, James S., Haque, Tamanna Z., Larkin, Karilyn T. M., Long, Meixiao, Mims, Alice S., Vasu, Sumithira, Wall, Sarah A., Byrd, John C., Lustberg, Mark, Walker, Alison R., Grieselhuber, Nicole R.

Get full text

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance) by Roboz, Gail J., Mandrekar, Sumithra J., Desai, Pinkal, Laumann, Kristina, Walker, Alison R., Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Attar, Eyal C., Stock, Wendy, Bloomfield, Clara D., Kohlschmidt, Jessica, Mrózek, Krzysztof, Hassane, Duane C., Garraway, Levi, Jané-Valbuena, Judit, Baltay, Michele, Tracy, Adam, Marcucci, Guido, Stone, Richard M., Larson, Richard A.

“…Novel treatment strategies are needed for older patients with acute myeloid leukemia (AML). This randomized phase 2 trial compared the efficacy and safety of…”
Get full text